GlassScriptPhysician profile
Mariam Noor
NPI 1689160426
$4,978.39
in general payments reported to CMS, 2019-2025
28 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $699 · 2023: $2,036 · 2024: $244 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,076 · Travel and Lodging: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.47 |
| Travel and Lodging | $1,052.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,908.19 | 2023-2025 | Vns Therapy |
| Ucb, INC. | $710.23 | 2021-2025 | Briviact, Fintepla |
| Abbvie INC. | $577.47 | 2021-2025 | |
| Neurelis, INC. | $349.00 | 2021-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $197.88 | 2021-2023 | Epidiolex |
| Eisai INC. | $139.05 | 2022-2023 | |
| Argenx US, INC. | $138.21 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $135.06 | 2022-2023 | Austedo Xr, Austedo |
| Csl Behring | $124.99 | 2023 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $93.75 | 2021-2023 | Gammagard |
| Acadia Pharmaceuticals INC | $78.49 | 2022-2025 | Nuplazid |
| Lundbeck LLC | $69.18 | 2022-2023 | Vyepti |
| Pfizer INC. | $50.37 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.85 | 2022 | |
| Alnylam Pharmaceuticals INC. | $48.47 | 2022-2023 | Onpattro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $45.98 | 2022 | |
| Sk Life Science, INC. | $42.25 | 2022 | |
| Alexion Pharmaceuticals, INC. | $35.50 | 2021-2023 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $33.00 | 2022-2023 | Firdapse |
| Biogen, INC. | $30.83 | 2023 | Spinraza |
| Avanir Pharmaceuticals, INC. | $21.33 | 2022 | |
| Kyowa Kirin, INC. | $18.78 | 2023 | Nourianz |
| Xeris Pharmaceuticals, INC. | $16.32 | 2023 | Keveyis |
| Amneal Pharmaceuticals LLC | $14.58 | 2023 | Rytary |
| Amylyx Pharmaceuticals, INC. | $14.39 | 2023 | Relyvrio |
| Otsuka America Pharmaceutical, INC. | $12.71 | 2023 | Nuedexta |
| Acorda Therapeutics, INC | $12.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Noor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.